Advanced Search

Medicare Compliance & Reimbursement

LABS:

CMS Alters C-Peptide Test Requirement

Published on Sat Feb 19, 2005

Lower limit is key.

For services performed on or after Dec. 17, 2004, a positive fasting beta cell autoantibody test can serve as an alternative to insulinopenia for the updated C-peptide testing requirement, the Centers for Medicare and Medicaid Services said Feb. 10.

Insulinopenia is a fasting C-peptide level less than or equal to 110 percent of the lower limit of normal. Patients with renal insufficiency must have a fasting C-peptide level that is less than or equal to 200 percent of the lower limit. The "lower limit" is contingent on the laboratory's measurement method.
 
To read more, go to www.cms.hhs.gov/manuals/pm_trans/R27NCD.pdf.
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Medicare Compliance & Reimbursement

View All